Applications of human hepatitis B virus preS domain in bio-and nanotechnology

作     者：Riki Toita Takahito Kawano Jeong-Hun Kang Masaharu Murata 

作者机构：Department of Biomaterials Faculty of Dental Science Kyushu University Department of Advanced Medical Initiatives Faculty of Medical Sciences Kyushu University Innovation Center for Medical Redox Navigation Kyushu University Division of Biopharmaceutics and Pharmacokinetics Department of Biomedical Engineering National Cerebral and Cardiovascular Center Research Institute 

出 版 物：《World Journal of Gastroenterology》 (世界胃肠病学杂志（英文版）)

年 卷 期：2015年第21卷第24期

页      面：7400-7411页

核心收录：

学科分类：1004[医学-公共卫生与预防医学(可授医学、理学学位)] 100401[医学-流行病与卫生统计学] 10[医学] 

基　　金：Supported by Health Labour Sciences Research Grant(Research on Publicly Essential Drugs and Medical Devices)from the Ministry of Health,Labour Welfare of Japan,a Special Coordination Funds for Promoting Science and Technology(SCF funding program"Innovation Center for Medical Redox Navigation"),a Grant-in Aid for Scientific Research,No.24300172 for Young-Scientists,No.25750176 from the Ministry of Education,Culture,Sports,Science and Technology of Japan,and the Fukuoka Foundation for Sound Health Cancer Research Fund 

主　　题：Hepatitis B virus Hepatocyte deliverysystem Vaccine Hepatitis B surface antigen Diagnosis 

摘      要：Human hepatitis B virus(HBV) is a member of the family Hepadnaviridae, and causes acute and chronic infections of the liver. The hepatitis B surface antigen(HBs Ag) contains the large(L), middle(M), and small(S) surface proteins. The L protein consists of the S protein, pre S1, and pre S2. In HBs Ag, the pre S domain(pre S1 + pre S2) plays a key role in the infection of hepatocytic cells by HBV and has several immunogenic epitopes. Based on these characteristics of pre S, several pre S-based diagnostic and therapeutic materials and systems have been developed. Pre S1-specific monoclonal antibodies(e.g., MA18/7 and KR127) can be used to inhibit HBV infection. A myristoylated pre S1 peptide(amino acids 2-48) also inhibits the attachment of HBV to Hepa RG cells, primary human hepatocytes, and primary tupaia hepatocytes. Antibodies and antigens related to the components of HBs Ag, pre S(pre S1 + pre S2), or pre S1 can be available as diagnostic markers of acute and chronic HBV infections. Hepatocyte-targeting delivery systems for therapeutic molecules(drugs, genes, or proteins) are very important for increasing the clinical efficacy of these molecules and in reducing their adverse effects on other organs. The selective delivery of diagnosticmolecules to target hepatocytic cells can also improve the efficiency of diagnosis. In addition to the full-length HBV vector, pre S(pre S1 + pre S2), pre S1, and pre S1-derived fragments can be useful in hepatocyte-specific targeting. In this review, we discuss the literature concerning the applications of the HBV pre S domain in bio- and nanotechnology.